OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

"D. H. W. Steel is a consultant for Alcon and Orbit Biomedical and has received research funding from Alcon, Astellas, Bayer, and Novartis. N. Patton is an advisory board member for Alcon. H. Hoerauf is a consultant for Alcon/Novartis, Alimera, Allergan, Bayer, and Oxurion; has received grants and/or funding from Alcon/Novartis, Allergan, Bayer, Bioeq/Formycon, Boehringer Ingelheim, Carl Zeiss Meditec, Heidelberg Engineering, Lutronic, Ophthotech, Regeneron, and Roche/Genentech; has received speaker fees and related travel expenses from Alcon/Novartis, Alimera, Allergan, Bayer, Heidelberg Engineering, Oxurion, and Thea Pharma; and has equity investments in 3M, Amgen, BASF, Bayer, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis, Roche, and Siemens. N. Patel has been a consultant for Alcon, Bayer, Novartis, Roche, Allergan, Bausch & Lomb, and Zeiss. J. Wachtlin has received speaker fees from Alcon, Allergan, Novartis, and Bayer; and is an advisory board member for Bayer and Novartis. T. Raber and P. Kozma-Wiebe are full-time employees of Oxurion NV. The remaining authors have no conflicting interests to disclose."

"The authors wish to acknowledge the principal investigators and study site staff who participated in the INJECT clinical study as well as all patients enrolled in the study. Medical writing assistance was provided by Zachary Harrelson and Duprane Pedaci Young from Fishawack Communications Inc. and was funded by Oxurion NV (formerly ThromboGenics)."